149669-42-1

Basic information

• Product Name: 5-BroMo-3-(4-piperidinyl)-1H-indole
• Synonyms: 5-BroMo-3-(4-piperidinyl)-1H-indole;5-Bromo-3-(piperidin-4-yl)-1H-indole;4-(5-Bromo-3-indolyl)piperidine
• CAS NO: 149669-42-1
• Molecular Formula: C13H15BrN2
• Molecular Weight: 279.1756
• Mol File: 149669-42-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 437.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.429±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 16.10±0.30(Predicted)
• CAS DataBase Reference: 5-BroMo-3-(4-piperidinyl)-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMo-3-(4-piperidinyl)-1H-indole(149669-42-1)
• EPA Substance Registry System: 5-BroMo-3-(4-piperidinyl)-1H-indole(149669-42-1)

Safety Data

• Hazardous Substances Data: 149669-42-1(Hazardous Substances Data)

Usage

General Description

5-Bromo-3-(4-piperidinyl)-1H-indole, also known as Bromo-MPPP, is a synthetic designer drug that belongs to the indole class of psychoactive substances. It is a derivative of the synthetic cathinone stimulant MPPP and is structurally related to other designer drugs like MDPV and alpha-PVP. Bromo-MPPP is known to act as a potent and selective dopamine-norepinephrine reuptake inhibitor, leading to increased levels of these neurotransmitters in the brain. This can result in stimulant and euphoric effects, as well as potential risks such as anxiety, paranoia, and cardiovascular problems. The drug is not approved for medical use and is primarily sold through illicit channels, where it is often marketed as a "research chemical" or "legal high." Bromo-MPPP's psychoactive properties and potential for abuse have led to its classification as a controlled substance in various jurisdictions.

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 127792-80-7 5-bromo-3-<1,2,3,6-tetrahydro-4-pyridinyl>-1H-indole 
• 41979-39-9 4-piperidone hydrochloride 

Relevant articles and documents

Synthesis and structure-activity relationships of novel histamine H 1 antagonists: Indolylpiperidinyl benzoic acid derivatives

A series of indolylpiperidinyl derivatives were prepared and evaluated for their activity as histamine H1 antagonists. Structure-activity relationship studies were directed toward improving in vivo activity and pharmacokinetic profile of our first lead (1). Substitution of fluorine in position 6 on the indolyl ring led to higher in vivo activity in the inhibition of histamine-induced cutaneous vascular permeability assay but lower selectivity toward 5HT2 receptor. Extensive optimization was carried out within this series and a number of histamine H1 antagonists showing potency and long duration of action in vivo and low brain penetration or cardiotoxic potential were identified. Within this novel series, indolylpiperidines 15, 20, 48, 51 and 52 exhibited a long half-life in rat and have been selected for further preclinical evaluation.

Bisindoles as tachykinin receptor antagonists

This invention provides a series of substituted bisindole propanamides which are useful as tachykinin receptor antagonists and as serotonin agonists. This invention also provides methods for the treatment of related disorders as well as pharmaceutical for